Controlling uric acid as a means to control cardiovascular disease, metabolic syndrome and lipids (Author's reply)

References (9)

1. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004; 44: 642-50
2. Nakagawa T, Tuttle KR, Short RA, Johnson RJ. Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nephrology 2005; 1: 80-6
3. Minami M, Ishiyama A, Takagi M, Omata M, Atarashi K. Effects of allopurinol, a xanthine oxidase inhibitor, on renal injury in hypercholesterolemia-induced hypertensive rats. Blood Press 2005; 14: 120-5
4. Osgood D, Corella D, Demissie S, Cupples LA, Wilson, PW, Meigs JB, et al. Genetic variation at the scavenger receptor class B type I gene locus determines plasma lipoprotein concentrations and particle size and interacts with type 2 diabetes: the Framingham study. J Clin Endocrinol Metab 2003; 88: 2869-79
5. Silverstein DM. Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol 2009; 24: 1445-52
6. Chen LY, Zhu WH, Chen ZW, Dai HL, Ren JJ, Chen JH, et al. Relationship between hyperuricemia and metabolic syndrome. J Zhejiang Univ Sci B 2007; 8: 593-8
7. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007; 120: 442-7
8. Emmerson B. Hyperlipidemia in hyperuricemia and gout. Ann Rheum Dis 1998; 58: 509-10
9. Becker M, Meenakshi J. Hyperuricemia and associated diseases. Rheum Dis Clin North Am 2006; 32: 275-93.